Phase II study of alemtuzumab (CAMPATH-1®) in patients with HTLV-1-associated adult T-cell leukemia/lymphoma

PURPOSE: Therapeutic regimens for ATL are limited with unsatisfactory results, thereby warranting development of novel therapies. This study investigated antitumor activity and toxicity of alemtuzumab with regard to response, duration of response, progression free survival, and overall survival in p...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Sharma, Kamal, Janik, John E., O’Mahony, Deirdre, Stewart, Donn, Pittaluga, Stefania, Stetler-Stevenson, Maryalice, Jaffe, Elaine S., Raffeld, Mark, Fleisher, Thomas A., Lee, Cathryn C., Steinberg, Seth M., Waldmann, Thomas A., Morris, John C.
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5215752/
https://ncbi.nlm.nih.gov/pubmed/27486175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1022
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars